Skip to main content
. 2020 Jul 10;9(14):e015897. doi: 10.1161/JAHA.119.015897

Figure 2. Adjusted hazard ratios and 95% CIs comparing use of phosphodiesterase type 5 inhibitors (vs no use) for the primary end point of pump thrombosis or ischemic stroke, by various subgroups.

Figure 2

INTERMACS indicates Interagency Registry for Mechanically Assisted Circulatory Support; LDH, lactate dehydrogenase; and LVAD, left ventricular assist device.